M&A Corner
FTC Lawsuit Holds Up IQVIA’s Advertising Acquisition of Propel Media31 Jul 2023
The acquisition of online marketing firm Propel Media by IQVIA is facing delays as the Federal Trade Commission (FTC) reviews... Continue Reading
|
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments31 Jul 2023
ABVC BioPharma, Inc. has signed a term sheet to advance a partnership with Zhonghui United Technology Group Co., Ltd. to... Continue Reading
|
Solar Biotech Acquires Noblegen31 Jul 2023
Solar Biotech Inc., a biomanufacturing solutions provider based in Norton, Virginia, has acquired Noblegen, a digital biology company in Canada.... Continue Reading
|
Eli Lilly Announces $2.4B Acquisition of Immunology Company Dice Therapeutics31 Jul 2023
Eli Lilly is set to acquire Dice Therapeutics for $2.4 billion in cash, providing a 40% premium on the smaller... Continue Reading
|
AstraZeneca, Pfizer Ink Potential $1B Gene Therapy Deal31 Jul 2023
AstraZeneca’s subsidiary, Alexion, is acquiring a portfolio of preclinical gene therapies and technologies from Pfizer in a deal worth up... Continue Reading
|
Biogen Agrees to Buy Reata Pharmaceuticals in Deal Valued at $7.3B31 Jul 2023
Biogen Inc. (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals (NASDAQ: RETA) for $172.50 per share in cash, valuing the... Continue Reading
|
RapidAI Secures $75M for AI-Driven Stroke Care Solutions31 Jul 2023
San Mateo-based digital health company, RapidAI, has raised $75 million in Series C funding, led by Vista Credit Partners, a... Continue Reading
|
Octave Bioscience Scores $30M for Neurodegenerative Disease Offerings31 Jul 2023
Octave Bioscience has raised an additional $30 million in an extension of its Series B funding round, with participation from... Continue Reading
|
Microsoft, Blue Shield of California Partner for Integrated Data Hub31 Jul 2023
Healthcare insurer Blue Shield of California has teamed up with Microsoft to create the Experience Cube, an integrated data hub... Continue Reading
|
Editas, Azzur Expand Manufacturing Partnership.31 Jul 2023
Editas Medicine (NASDAQ:EDIT) and Azzur Group have extended their contract to develop and manufacture cell therapies in pre-clinical and early... Continue Reading
|